RT Journal Article
SR Electronic
T1 Longitudinal changes in IgG-type SARS-CoV-2 antibody titers after COVID-19 vaccination and, prominent increase in antibody titers when infected after vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.04.23285414
DO 10.1101/2023.02.04.23285414
A1 Hiroshi Kusunoki
A1 Michiko Ohkusa
A1 Rie Iida
A1 Ayumi Saito
A1 Mikio Kawahara
A1 Kazumi Ekawa
A1 Nozomi Kato
A1 Keita Yamasaki
A1 Masaharu Motone
A1 Hideo Shimizu
YR 2023
UL http://medrxiv.org/content/early/2023/03/01/2023.02.04.23285414.abstract
AB [Objective]Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody titers level and duration of elevated levels are considered important indicators for confirming the efficacy of coronavirus disease 2019 (COVID–19) vaccines. The objective of this study was to demonstrate the changes in antibody titers after the second and third doses of the COVID–19 vaccine, and to determine the antibody titers in cases of spontaneous infection with SARS-CoV-2 after vaccination.[Materials and Methods]From June 2021 to February 2023, IgG-type SARS-CoV-2 antibody titers were measured in 127 participants, including 74 outpatients and 53 staffs, at the Osaka Dental University Hospital (65 males and 62 females, mean age 52.3 ± 19.1 years).[Results]Consistent with previous reports, the SARS-CoV-2 antibody titer decreased with time, not only after the second dose, but also after the third dose of the vaccine if there is no spontaneous COVID–19 infection. We also confirmed that the third booster vaccination was effective in increasing the antibody titer.21 cases of natural infections were observed after administering two or more doses of the vaccine. 13 of these patients had post-infection antibody titers exceeding 40,000 AU/mL, and some cases continued to maintain antibody titers in the tens of thousands of AU/mL even after more than 6 months had passed since infection.[Conclusion]The rise in and duration of antibody titers against SARS-CoV-2 are considered important indicators for confirming the efficacy of novel COVID–19 vaccines. A longitudinal follow-up of antibody titers after vaccination in larger studies is warranted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the ethics committee of Osaka Dental University Hospital (2022-10)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.